science-news
Genmab’s DuoBody platform
I was interested in learning about the scientific core of Genmab’s business model. Looking for this, I found two key papers: the 2013 controlled Fab-arm exchange paper and the 2013 scale-up and manufacturing paper. The conceptual origin sits a bit earlier, in the IgG4 literature, where Fab-arm exchange shows